Evidence record · ER-MT2-TANNING-010
Does Melanotan II increase tanning?
Melanotan II increases visible skin pigmentation
Melanotan II increased skin pigmentation in a very small placebo-controlled human study, so the tanning effect is supported within those research conditions. That finding does not make the peptide authorised, safe, equivalent to a consumer product or protective against ultraviolet damage. Pigmentation and skin-cancer risk are separate questions.
Claim boundary
What this verdict covers
The supported claim is visible or measured pigmentation after the defined research compound. It does not include safe tanning, sun protection, mole safety or the quality of products sold online.
- Compound
- Melanotan II
- Population
- Three healthy men in an early controlled study
- Outcome
- Measured or visible pigmentation
- Record ID
- ER-MT2-TANNING-010
Evidence synthesis
What the research can support
An early placebo-controlled study in three healthy men reported increased pigmentation after Melanotan II exposure. The sample and duration were very limited, and the work was not a modern medicine-approval programme.
Why the confidence is moderate
A three-person study supports a physiological signal but gives a very imprecise estimate and cannot resolve uncommon or delayed harms. Product identity, sterility and impurity risks are not addressed by the tanning result.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-MT2-TANNING-010 addresses one bounded question: Does Melanotan II increase tanning?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Limited human, the verdict is Supported and confidence is Low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Placebo-controlled Melanotan II pigmentation study | The study reported increased pigmentation in exposed participants. | It did not establish long-term safety or sun protection. | 10 August 2026 |
| FDA bulk-substance safety page | FDA identifies safety and product-quality concerns for Melanotan II. | It does not test every consumer product. | 10 August 2026 |
| MHRA products database | The database is the official route for checking current UK medicine authorisations. | It does not verify an unlicensed seller or vial. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Melanotan II for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
An early placebo-controlled study in three healthy men reported increased pigmentation after Melanotan II exposure. The sample and duration were very limited, and the work was not a modern medicine-approval programme. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Melanotan II authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Athletes should check the current WADA Prohibited List and obtain sport-specific advice. An experimental or non-approved peptide may fall within the S0 category even when it is not named individually. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
A regulated development programme with larger controlled studies, dermatological surveillance, long follow-up and a fully characterised product. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation